Neurogene(NASDAQ) NGNE

Neurogene makes medicines for people with rare brain diseases. These treatments help families facing serious health problems. The company builds its own products in a Texas factory.

Targeting Rare Brain Disorders

• NGN-401: Gene therapy for Rett syndrome, a rare brain disease, currently in late-stage clinical testing.
• EXACT Technology: Tool designed to control gene expression, which determines how much medicine is active in cells.
• Manufacturing Facility: Houston-based plant producing materials for clinical trials and potential commercial use.
• Discovery Pipeline: Early research focused on finding treatments for other complex neurological conditions.

Strategic Steps and Partnerships

• Partnered with University of Edinburgh in 2020 to develop specialized gene regulation technology.
• Licensed a manufacturing process from Virovek in 2020 for use in drug production.
• Selected by the FDA for the START Pilot Program in June 2024 to accelerate drug development.
• Earned Breakthrough Therapy status in February 2026 for its lead treatment for Rett syndrome.

How Does Neurogene Stand Out?

Neurogene uses its own EXACT technology to fine-tune gene expression and avoid toxic side effects. The company operates a dedicated 42,000 square foot factory in Houston to control production quality and timing.

A Look at the Numbers

• Net loss deepened to $24.7 million in Q4 2025, worsening 26.8% from the previous year.
• Operating income reached negative $27.5 million in Q4 2025, worsening 28% year-over-year.
• Total cash and short-term investments stood at $269 million as of December 31, 2025.
• Free cash flow reached negative $16.8 million in Q4 2025, improving 4.7% from the prior year.

Bottom Line

Neurogene has evolved from a research startup to a clinical-stage company with its own manufacturing capabilities. Its focus on controlled gene expression aims to treat diseases that traditional gene therapies cannot address.